A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of \*\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\*\* as first-line treatment for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric Carcinoma
BIOLOGICAL: Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine|BIOLOGICAL: Tislelizumab+Oxaliplatin+Capecitabine
Progression-Free Survival, 24 months
Overall Survival, up to 5 years|Objective Response Rate, 24 months|Disease Control Rate, 24 months|Duration of Response, 24 months|Patient-Reported Outcomes, 24 months|Adverse Events, 24 months
The purpose of this study is to evaluate the efficacy and safety of \*\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\*\* as first-line treatment for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma.